Approval of new drugs by the Therapeutic Goods Administration is no guarantee that they are superior or even equivalent to drugs already on the market. The drug evaluation process only assesses quality, safety and efficacy, not the therapeutic value of a drug. Assessments of the value of new drugs from Canada, France and the USA all show that at best one third of new drugs offer some additional clinical benefit and perhaps as few as 3% are major therapeutic advances.
Drug companies are spending an estimated $1-1.5 billion per year promoting their drugs in Australia. 1 One group of drugs that are heavily promoted as being better than existing products are single enantiomers of drugs that were initially introduced as racemic mixtures. The two prime examples of this phenomenon are esomeprazole which is the S-enantiomer of racemic S,R-omeprazole, and escitalopram which is the S-enantiomer of racemic citalopram. Evaluation of both new products has not demonstrated any advantages in safety or effectiveness, over their respective racemic mixtures at appropriate doses. 2, 3 The main reason for bringing both to market seems to have been the imminent expiry of the patents of the original products which would result in generic competition and a significant loss of market share. Even when comparative trials exist they may be too small or short to provide any meaningful conclusions. For example, when cisapride was marketed in Canada there were nine published randomised controlled trials, but in total only 254 patients were enrolled. Trials with small numbers have at least two major shortcomings: they will almost certainly miss serious, but relatively rare adverse effects, and it is impossible to identify sub-groups of patients in whom the drug may be particularly effective or ineffective. Cisapride has now been completely withdrawn from the market in North America and its use restricted in Australia because of serious adverse effects that only showed up after marketing. Other drugs that are intended for long-term use are often only studied in short-term randomised controlled trials. Short-term trials cannot reliably predict the ultimate benefit, or lack thereof, of drugs that are going to be taken for years. For example, none of the seven trials of losartan that were published when it was introduced in Canada was longer than 26 weeks. 5 Drug approvals are often based on surrogate end-points,
In this issue…
The launch of the bright new design of Australian Prescriber is an appropriate time to consider the glossy world of advertising. Joel Lexchin tells us that new drugs do not always live up to the promises of marketing campaigns, and Agnes Vitry comments on the insidious growth of advertising drugs to the public. Fortunately, Medicines Australia has imposed sanctions on companies which have breached the advertising code of conduct for prescription drugs.
Patients want information not advertising, so Christopher Newell gives advice on how to find a support group, while Anne Robinson and Susan Day tell us how to look for medical evidence electronically.
An area where the medical evidence may be confused is the interaction of paracetamol and alcohol. Garry Graham, Kieran Scott and Ric Day conclude that paracetamol is still a suitable analgesic for heavy drinkers.
Dental patients taking warfarin
Editor, -The management of patients taking anticoagulants who require dental extractions is of interest to both medical and dental practitioners. 1 It has been common practice to discontinue anticoagulants to reduce the risk of postextraction bleeding. Lately however some studies have questioned the need for reduction or withdrawal of warfarin when the INR was within the therapeutic range.
We have recently reported a study involving 70 patients who were taking warfarin for a variety of medical conditions and required dental surgery. 2 
